clinical trial · NCT06563856
A Study of TEPEZZA Subcutaneous Administration in Healthy Adults
Amgen·phase1·completed·n = 37
BioavailabilityBioequivalenceTEPEZZAEDP
brief summary
The primary objective of this study is to assess the pharmacokinetics (PK) parameters of a single subcutaneous (SubQ) infusion of TEPEZZA with and without ENHANZE™ Drug Product (EDP) at 2 dose levels in healthy adult participants.
started
Sep 22, 2020
primary completion
May 27, 2021
completion
May 27, 2021
last updated
Aug 21, 2024
official title
A Phase 1, Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TEPEZZA Subcutaneous Administration in Healthy Adult Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol